A Phase 2 Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Jan 2018
At a glance
- Drugs Bortezomib (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 09 Jan 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2020.
- 09 Jan 2018 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2019.
- 23 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by Clinicaltrials.gov record.